

PC25402A  
USSN 10/657,033

4-4-05  
EV496344805US

IFW  
Certificate of Mailing (37 C.F.R. §1.10):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail (#EV496344805US) in an envelope  
addressed to: Mail Stop:Amendments,  
Commissioner for Patents, PO Box 1450,  
Alexandria, VA 22313-1450 on this  
31<sup>st</sup> day of March 2005.

s/   
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
Paul John Edwards, et al.

Serial No.: 10/657,033

Filed: September 5, 2003

For: Pyrazole Derivatives

Group Art Unit: 1626

Examiner: SOLOLA, TAOFIQ A

Confirmation No.: 9054

Mail Stop: Amendments  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Sir:

In response to the Restriction Requirement dated March 10, 2005, Applicants elect Group I, encompassing Claims 1 to 9 of the instant application. This election is with traverse, on the grounds that Group VII should be rejoined with Group I, and that the process claims of Group V should also be rejoined with Group I upon a finding that the process claims are found allowable.

Applicants also submit that the elected disease is HIV, which is clearly supported by the specification.

Further, Applicants submit that Example 3 is elected as a representative compound of the elected Group. Example 3 is a compound of Formula (I) wherein:


R<sup>0</sup> is ethylene; R<sup>1</sup> is phenyl substituted (in position 4) by SOyR<sup>5</sup> where y is 2 and R<sup>5</sup> is methyl;  
R<sup>2</sup> is hydrogen; R<sup>3</sup> is ethyl; and R<sup>4</sup> is 3,5-dicyanophenyl.

Applicants also respectfully submit that Applicants orally elected Group I (with traverse) in a phone call to the Examiner on March 7, 2005. Applicants submit that the instant election is consistent with that oral election of Group I.

Applicants believe that no extension of time is necessary for this response. However, in the event that an extension of time is required, for which Applicants hereby petition, authorization is hereby provided to charge any fees required under 37 CFR § 1.17, or to credit any overpayment to Deposit Account No. 500329.

Respectfully submitted,

Date: March 31, 2005

  
Keith D. Hutchinson  
Attorney For Applicants  
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233